Drugs Containing Excipient (Inactive Ingredient) POLYCARBOPHIL

Branded drugs containing POLYCARBOPHIL excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	CRINONE	progesterone	0023-6150	POLYCARBOPHIL
Exeltis USA Inc	NUVESSA	metronidazole	0642-7466	POLYCARBOPHIL
Akorn	AZASITE	azithromycin monohydrate	17478-307	POLYCARBOPHIL

Generic drugs containing POLYCARBOPHIL excipient

Company	Ingredient	NDC	Excipient
Allergan Inc	progesterone	0023-6150	POLYCARBOPHIL
Exeltis USA Inc	metronidazole	0642-7466	POLYCARBOPHIL
Akorn	azithromycin monohydrate	17478-307	POLYCARBOPHIL

Polycarbophil Market Dynamics and Financial Trajectory

Last updated: August 23, 2026

Polycarbophil is a mature, low-cost pharmaceutical excipient with demand concentrated in over-the-counter bulk-forming laxatives, vaginal moisturizers, oral dosage-form binders, and controlled-release systems. Its commercial outlook is stable rather than high-growth. Public companies do not report polycarbophil revenue as a separate line item, so the financial trajectory must be assessed through product exposure, regulatory status, supplier economics, and substitution risk.

The strongest commercial position is in calcium polycarbophil products such as FiberCon. The principal risks are raw-material qualification, price competition, substitution by psyllium and other polymers, and limited differentiation at the excipient level.

What is polycarbophil and how is it used in pharmaceuticals?

Polycarbophil is a crosslinked polyacrylic acid polymer that absorbs water and expands substantially. In finished products, it is used as an absorbent, bulking agent, mucoadhesive, thickener, and sustained-release component.

Calcium polycarbophil is the most visible pharmaceutical form. It is used in bulk-forming laxatives, where the polymer absorbs liquid and increases stool bulk. The FDA classifies bulk-forming agents, including calcium polycarbophil, within the OTC laxative framework under 21 C.F.R. Part 334.[1]

Attribute	Polycarbophil profile
Chemical class	Crosslinked polyacrylic acid polymer
Common pharmaceutical form	Calcium polycarbophil
Principal functions	Absorbent, bulking agent, mucoadhesive, thickener
Main product categories	OTC laxatives, vaginal moisturizers, oral formulations
Primary route	Oral and vaginal
Regulatory status	Established excipient and OTC active ingredient in certain products
Commercial maturity	Mature, low-growth, qualification-sensitive
Main substitutes	Psyllium, methylcellulose, polyethylene glycol, carbomer, sodium hyaluronate

Polycarbophil is distinct from carbomer, although both are crosslinked acrylic-acid polymers. Formulation performance depends on crosslink density, particle size, swelling capacity, neutralization, viscosity, residual monomer profile, and microbial quality.

How large is the polycarbophil pharmaceutical market?

No reliable public source reports a standalone global market size or revenue pool for polycarbophil. Market-research reports generally group it with carbomers, acrylic polymers, specialty excipients, or pharmaceutical polymers. Manufacturers also do not typically disclose polycarbophil sales separately.

The addressable market is therefore best understood as a narrow subsegment of the pharmaceutical excipients market with four demand pools:

1. OTC bulk-forming laxatives.
2. Vaginal moisturizers and lubricating products.
3. Oral formulations using swelling or mucoadhesive polymers.
4. Research and development programs involving controlled release or gastrointestinal retention.

The largest established demand pool is likely OTC consumer healthcare. This market has recurring volume, but it is mature and exposed to retailer private-label competition. Prescription-drug use is more limited and depends on formulation-specific performance rather than broad API demand.

What drives polycarbophil demand?

Demand is linked to finished-dose volume, not the value of the polymer itself. The main commercial drivers are:

• Continued use of bulk-forming laxatives.
• Growth in self-care gastrointestinal products.
• Demand for non-systemic vaginal moisturizers.
• Need for polymers with high water absorption and bioadhesion.
• Relatively simple incorporation into tablets, capsules, gels, and topical systems.
• Availability of compendial or well-characterized grades.

The main constraint is low excipient spend per finished unit. Even when demand rises, the financial benefit to an excipient producer can be limited because the polymer is usually a small percentage of product cost.

What products contain polycarbophil?

Calcium polycarbophil laxatives

FiberCon is the best-known commercial product associated with calcium polycarbophil. The product labeling identifies calcium polycarbophil as the active ingredient and describes its use as a bulk-forming laxative.[2]

The product is sold in tablet form and competes with psyllium-based products, methylcellulose products, polyethylene glycol products, stimulant laxatives, and stool softeners. Competition is determined by consumer recognition, retail placement, price, tolerability, dosing convenience, and physician recommendation.

Vaginal moisturizers

Polycarbophil is also used in vaginal moisturizers and related products. Its water-absorbing and mucosal-retention properties allow a formulation to remain in contact with tissue longer than a conventional aqueous gel. FDA labeling databases identify polycarbophil-containing drug products and OTC products in vaginal and mucosal applications.[3]

These products compete with formulations based on:

• Carbomer.
• Glycerin.
• Hyaluronic acid or sodium hyaluronate.
• Silicone and oil-based systems.
• Water-based lubricants.
• Prescription estrogen products, where the therapeutic indication differs.

The commercial value of polycarbophil in this segment depends more on finished-product branding and claims than on the polymer itself.

Oral and controlled-release formulations

Polycarbophil can provide swelling, matrix formation, adhesion to mucosal surfaces, and release-rate control. These functions make it relevant to oral tablets, gastrointestinal delivery systems, and experimental formulations.

The application is technically attractive but commercially narrower. Pharmaceutical developers often choose polymers based on regulatory history, release performance, supplier support, and availability of reproducible grades. Established alternatives include hypromellose, polyethylene oxide, carbomer, sodium alginate, xanthan gum, and cellulose derivatives.

What is the FDA regulatory status of polycarbophil?

Polycarbophil has a split regulatory position.

For certain OTC products, calcium polycarbophil is regulated as an active ingredient under the FDA laxative monograph framework. For other products, polycarbophil is used as an inactive excipient or functional polymer. The FDA Inactive Ingredient Database records excipient use by route and dosage form, but the database does not establish a universal approval for every formulation or concentration.[4]

The practical regulatory position is:

Regulatory issue	Commercial implication
OTC laxative monograph	Supports established calcium polycarbophil products
Inactive Ingredient Database listing	Helps support prior-use arguments for specific routes and forms
Product-specific dosage and route	Still require formulation and regulatory assessment
Compendial quality	Can reduce qualification friction where applicable
New delivery system	May require extensive safety and performance data

Polycarbophil does not have the same regulatory profile as a new molecular entity. Its value comes from established use, reproducible performance, and supplier documentation.

What patents protect polycarbophil products?

The base polymer is not a high-value modern patent asset. Core composition and manufacturing concepts for crosslinked polyacrylic-acid polymers are generally old, and any early foundational patents would typically have expired.

The active patent opportunities are product-specific:

• Dosage forms containing calcium polycarbophil.
• Vaginal formulations with specified retention or moisturizing characteristics.
• Combination products.
• Controlled-release matrices.
• Particle-size and swelling profiles.
• Manufacturing processes that produce a defined polymer grade.
• Medical-use claims tied to a particular delivery system.

Are there Paragraph IV challenges involving polycarbophil?

Paragraph IV litigation is not a central feature of the polycarbophil market. The most visible calcium polycarbophil products are OTC products rather than high-value patented prescription drugs. Generic competition usually enters through private-label or store-brand products, regulatory monograph compliance, and contract manufacturing rather than through high-profile Hatch-Waxman litigation.

The FDA Orange Book is primarily relevant to approved prescription and certain other listed drug products. It is not a comprehensive patent database for excipient suppliers or OTC monograph products.[5] A polycarbophil supplier should therefore distinguish:

• Patents covering the polymer itself.
• Patents covering a finished dosage form.
• Patents covering a method of treatment.
• Regulatory exclusivity associated with a specific approved product.
• Trade secrets covering polymerization and purification.

How strong is the polycarbophil patent estate?

The estate is weak at the base-material level and potentially moderate at the formulation level.

Layer of protection	Estimated strength	Reason
Basic polycarbophil composition	Low	Mature polymer technology and likely expired foundational claims
Calcium polycarbophil laxative concept	Low	Established OTC category with substantial substitution
Proprietary particle-size grade	Moderate	Can support performance-based claims if technically narrow
Vaginal moisturizer formulation	Moderate	Retention, dosing, and combination claims may be defensible
Controlled-release system	Moderate to high	Patent value depends on demonstrated release and clinical performance
Manufacturing process	Moderate	Trade-secret protection may be more important than patents

Freedom-to-operate analysis must focus on the finished formulation and manufacturing process rather than on the generic identity of polycarbophil.

What manufacturing and intellectual-property barriers affect supply?

Manufacturing is not conceptually complex, but reproducibility is commercially important. Key control points include crosslinking conditions, neutralization, washing, drying, milling, residual acrylic acid, residual crosslinker, particle-size distribution, swelling ratio, viscosity, and bioburden.

A qualified pharmaceutical grade must meet customer-specific specifications. A supplier that sells industrial acrylic polymer may not be interchangeable with a supplier qualified for oral or vaginal pharmaceutical use.

The principal barriers are:

• Customer qualification and change-control requirements.
• Validation of polymer performance in the finished dosage form.
• Long regulatory documentation cycles.
• Consistent particle-size and swelling characteristics.
• Control of residual monomer and extractables.
• Supply continuity for acrylic-acid and crosslinking raw materials.
• Site-change notification obligations.
• Ability to support audits and regulatory filings.

These barriers create switching costs even when the polymer is nominally commoditized. The switching cost is greater for a controlled-release product than for a simple OTC tablet.

How does polycarbophil compare with competing excipients?

Excipient	Main advantage	Main limitation	Competitive position
Polycarbophil	High swelling and mucoadhesion	Narrower supplier and application base	Strong in selected OTC and mucosal products
Psyllium	Consumer familiarity and natural positioning	Larger dosing volume and variable sensory profile	Major laxative competitor
Methylcellulose	Established bulk-forming profile	Different hydration and processing behavior	Direct OTC substitute
Polyethylene glycol	Predictable osmotic effect	Not a structural swelling polymer	Strong laxative competitor
Carbomer	High viscosity at low concentration	pH and electrolyte sensitivity	Strong topical and mucosal competitor
Sodium hyaluronate	Premium positioning and tissue-hydration claims	Higher material cost	Premium vaginal and topical competitor
Hypromellose	Broad regulatory history and controlled-release use	Different gel and release profile	Major oral formulation alternative

Polycarbophil is most defensible when its swelling, adhesion, or residence-time profile produces a measurable product advantage. It is less defensible when used only as a generic thickener or absorbent.

What is the financial trajectory for polycarbophil?

The financial trajectory is likely stable with modest volume growth and continuing price pressure. Public financial statements do not isolate polycarbophil revenue, gross margin, or operating profit. The economic model is therefore driven by market structure rather than reported segment results.

Base-case outlook

The base case is a mature excipient market with:

• Low-to-moderate volume growth.
• Flat or declining real prices.
• Stable demand from existing OTC products.
• Periodic growth from private-label products.
• Limited contribution from novel prescription formulations.
• Margin protection for qualified suppliers with reliable documentation.
• Margin compression for undifferentiated industrial-grade suppliers.

Upside factors

Potential upside comes from:

• Expansion of branded or private-label bulk-forming laxatives.
• Increased use of vaginal moisturizers.
• New mucoadhesive oral delivery systems.
• Reformulation away from animal-derived or less consistent materials.
• Premium grades with narrower particle-size distribution.
• Dual sourcing requirements that create demand for second-qualified suppliers.

Downside factors

The main downside risks are:

• Substitution by psyllium, PEG, methylcellulose, carbomer, or hyaluronic acid.
• Retail price competition.
• Customer consolidation.
• Raw-material cost inflation.
• Manufacturing-site changes that trigger requalification.
• Product discontinuation by a major consumer-healthcare brand.
• Inability to differentiate pharmaceutical grade from lower-cost industrial material.

Which companies are exposed to polycarbophil economics?

Exposure is more visible among finished-product manufacturers and consumer-healthcare companies than among diversified excipient producers. Relevant commercial participants include:

• Owners and marketers of calcium polycarbophil laxative brands.
• Private-label OTC manufacturers.
• Contract manufacturers producing tablets and vaginal products.
• Specialty polymer suppliers.
• Distributors of pharmaceutical-grade acrylic polymers.
• Pharmaceutical developers using polycarbophil in controlled-release formulations.

The largest financial exposure generally sits with the finished-product owner because the consumer brand captures pricing, shelf placement, and gross margin. The polymer supplier captures a smaller share of value but may benefit from long-term qualification and repeat orders.

What is the geographic coverage of polycarbophil demand?

The United States is the most commercially visible market because calcium polycarbophil has an established OTC laxative position and products are marketed through major retail channels. European and Asian demand is more fragmented across pharmaceutical, medical-device, cosmetic, and consumer-healthcare classifications.

Geographic expansion can require separate review of:

• Excipient compendial status.
• OTC monograph or self-care regulation.
• Medical-device classification for vaginal moisturizers.
• Local labeling requirements.
• Residual-monomer limits.
• Import and site-registration rules.
• Local supplier qualification.

The same polymer may be regulated differently depending on whether it is sold as an active ingredient, excipient, medical-device component, or cosmetic ingredient.

What generic launch scenarios exist for polycarbophil products?

Three launch models are commercially realistic:

1. Private-label OTC launch. The entrant uses calcium polycarbophil in a tablet or capsule and competes on retail price.
2. Brand-generic substitution. A manufacturer targets an established product with comparable strength, labeling, and consumer use.
3. Formulation-led launch. A company uses polycarbophil in a differentiated vaginal, oral, or controlled-release product.

The first model has the lowest technical barrier but the highest price pressure. The third has greater patent and regulatory value but requires formulation data and stronger commercialization capabilities.

What licensing deals and settlement agreements affect polycarbophil?

Polycarbophil is not generally associated with major publicly disclosed licensing transactions or high-value Paragraph IV settlements. Commercial agreements are more likely to involve:

• Excipient supply contracts.
• Private-label manufacturing.
• Brand divestitures.
• Regional distribution.
• Formulation development.
• Technology transfer and second-source qualification.

The absence of prominent public settlements is consistent with a mature OTC and excipient market rather than a high-value patented prescription franchise.

Key Takeaways

• Polycarbophil is a mature acrylic polymer used mainly in bulk-forming laxatives, vaginal moisturizers, and selected oral delivery systems.
• Calcium polycarbophil has the clearest commercial position through OTC laxative products such as FiberCon.
• No dependable public standalone revenue or market-size disclosure exists for polycarbophil.
• Base-material patent protection is weak; formulation, process, and performance claims provide the main remaining IP value.
• Paragraph IV litigation and Orange Book exposure are limited compared with prescription-drug markets.
• Financial performance is likely stable but price-sensitive, with qualified pharmaceutical grades receiving the strongest margins.
• The principal competitive threats are psyllium, polyethylene glycol, methylcellulose, carbomer, and sodium hyaluronate.
• Manufacturing consistency, regulatory documentation, and customer qualification are more important barriers than basic polymer chemistry.
• The strongest investment case is a qualified supplier or differentiated finished product, not an undifferentiated commodity polymer.

FAQs

Is polycarbophil an active pharmaceutical ingredient or an excipient?

It can be either, depending on the product. Calcium polycarbophil is used as the active ingredient in certain OTC bulk-forming laxatives. Polycarbophil is used as an excipient or functional polymer in other formulations.

Does polycarbophil have biosimilar competition?

No. Biosimilars apply to biologic products. Polycarbophil is a synthetic polymer and competes with generic excipients, alternative polymers, and private-label finished products.

Is calcium polycarbophil safer than psyllium?

They are different bulk-forming agents with different labeling, hydration, tolerability, and dosing characteristics. Comparative safety depends on the product label, dose, hydration, patient condition, and risk of obstruction.

Can a new company enter the polycarbophil supply market?

Yes, but commercial entry requires reproducible pharmaceutical-grade manufacturing, customer qualification, residual-monomer controls, regulatory documentation, and supply continuity. Technical synthesis alone is insufficient for major pharmaceutical customers.

Does polycarbophil have long-term growth potential?

Its base market is mature. Higher growth is more likely in differentiated delivery systems, vaginal products, specialty grades, and private-label consumer healthcare than in commodity excipient volume.

References

1. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 334: Anti-caries drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-334

2. DailyMed. (n.d.). FiberCon calcium polycarbophil tablet labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

3. U.S. National Library of Medicine. (n.d.). DailyMed drug labels and inactive ingredient information. https://dailymed.nlm.nih.gov/dailymed/

4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book